Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.
Twenty-four acutely ill schizophrenic patients (DSM-III-R), 18-42 years old, were treated for 6 weeks with sulpiride. Sulpiride was administered in three different daily dosages (starting with 400, 800 or 1200 mg) according to a double blind randomized administration schedule. The monoamine metabolites (MAM) homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA), 4-hydroxy-3-methoxy-phenylglycol (HMPG) and the amino acids tyrosine, tryptophan, glutamate and glutamine were measured in serum before treatment and once a week during treatment. There were no significant differences between healthy controls and schizophrenic patients in serum levels of monoamine metabolites and amino acids before treatment. There was no dose-response effect of sulpiride on serum levels of the monoamine metabolites or the amino acids. The results are therefore based on the whole group of patients. During treatment the HMPG levels were reduced at all points in time. The serum level of HVA was significantly reduced after 6 weeks. The 5-HIAA and the amino acid levels were not changed during treatment. There were no significant correlations among the monoamine metabolites before treatment. During treatment, however, significant correlations were found among MAM and amino acids. Since the biochemical findings during the treatment were not related to the dose or the concentration of sulpiride the results may be related to secondary biochemical effects of sulpiride and/or to changes in the clinical state following treatment.
Alfredsson
G
G
Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden.
Wiesel
F A
FA
D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000097:blood*; D015306:Biogenic Monoamines / Q000097:blood*; D005260:Female; D005971:Glutamates / Q000097:blood / Q000134:cerebrospinal fluid; D005973:Glutamine / Q000097:blood; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008297:Male; D015093:Meglutol / Q000134:cerebrospinal fluid; D012559:Schizophrenia / Q000097:blood* / Q000134:cerebrospinal fluid / Q000188:drug therapy; D013469:Sulpiride / Q000097:blood / Q000627:therapeutic use*; D014364:Tryptophan / Q000097:blood; D014443:Tyrosine / Q000097:blood
D000596:Amino Acids; D015306:Biogenic Monoamines; D005971:Glutamates; D005973:Glutamine; D014443:Tyrosine; D006897:Hydroxyindoleacetic Acid; D013469:Sulpiride; D014364:Tryptophan; D015093:Meglutol; D006719:Homovanillic Acid